Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Samll ,prospective, Observational, Pilot study to assess the sustained effect of Omalizumab after its discontinuation in severe Asthmatic patients

Trial Profile

Samll ,prospective, Observational, Pilot study to assess the sustained effect of Omalizumab after its discontinuation in severe Asthmatic patients

Completed
Phase of Trial: Phase IV

Latest Information Update: 29 Nov 2018

At a glance

  • Drugs Omalizumab (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Nov 2018 New trial record
    • 31 Oct 2018 Primary endpoint (exacerbation rates, skin prick test [SPT] positivity and Asthma Control Test [ACT] scores at the time of discontinuation and 6 and 12 months thereafter) has been met as per results published in the Clinical Therapeutics
    • 31 Oct 2018 Primary endpoint (FeNO levels for 1 year after treatment discontinuation) has not been met as per results published in the Clinical Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top